These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9176707)

  • 1. A vision of cell death: insights into immune privilege.
    Ferguson TA; Griffith TS
    Immunol Rev; 1997 Apr; 156():167-84. PubMed ID: 9176707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A vision of cell death: Fas ligand and immune privilege 10 years later.
    Ferguson TA; Griffith TS
    Immunol Rev; 2006 Oct; 213():228-38. PubMed ID: 16972907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell death and immune privilege.
    Ferguson TA; Green DR; Griffith TS
    Int Rev Immunol; 2002; 21(2-3):153-72. PubMed ID: 12424841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response.
    Ferguson TA; Griffith TS
    Chem Immunol Allergy; 2007; 92():140-154. PubMed ID: 17264490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of FasL-induced apoptosis in immune privilege.
    Griffith TS; Ferguson TA
    Immunol Today; 1997 May; 18(5):240-4. PubMed ID: 9153956
    [No Abstract]   [Full Text] [Related]  

  • 6. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell death and the immune response: a lesson from the privileged.
    Ferguson TA; Griffith TS
    J Clin Immunol; 1997 Jan; 17(1):1-10. PubMed ID: 9049780
    [No Abstract]   [Full Text] [Related]  

  • 9. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
    O'Connell J
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.
    Griffith TS; Yu X; Herndon JM; Green DR; Ferguson TA
    Immunity; 1996 Jul; 5(1):7-16. PubMed ID: 8758890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Fas ligand is not a main mechanism used by tumors to counteract antitumor immunity.
    Chen CM; Song W; Kao JY; Zheng QD; Chen JJ
    Front Biosci; 2004 Jan; 9():448-56. PubMed ID: 14766381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
    O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
    J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas-ligand: privilege and peril.
    Green DR; Ware CF
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):5986-90. PubMed ID: 9177153
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: implications in immune privilege.
    Rajashekhar G; Loganath A; Roy AC; Mongelli JM
    Gynecol Oncol; 2003 Oct; 91(1):89-100. PubMed ID: 14529667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
    O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
    Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Fas ligand in conferring immune privilege to non-lymphoid cells.
    Guller S
    Ann N Y Acad Sci; 1997 Sep; 828():268-72. PubMed ID: 9329847
    [No Abstract]   [Full Text] [Related]  

  • 18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
    Stuart PM; Griffith TS; Usui N; Pepose J; Yu X; Ferguson TA
    J Clin Invest; 1997 Feb; 99(3):396-402. PubMed ID: 9022072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.